

<b>NCT ID</b>	NCT03475004
<b>Title</b>	Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2018-03-23
<b>Location</b>	Colorado, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Pembrolizumab, Bevacizumab, and Binimetinib
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03626922
<b>Title</b>	Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-08-13
<b>Location</b>	Florida, United States Illinois, United States Michigan, United States Minnesota, United States Pennsylvania, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Dexamethasone, oxaliplatin, Pembrolizumab, Pemetrexed, Alimta, Eloxatin, Keytruda
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04991948
<b>Title</b>	Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2021-08-05
<b>Location</b>	Florida, United States Belgium
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	CYAD-101, FOLFOX, Pembrolizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05239741
<b>Title</b>	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
<b>Phase</b>	Phase 3
<b>Date Added</b>	2022-02-15
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	5-Fluorouracil, Irinotecan, Leucovorin, oxaliplatin
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT02608385
<b>Title</b>	Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

<b>Phase</b>	Phase 1
<b>Date Added</b>	2015-11-18
<b>Location</b>	Illinois, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Pembrolizumab
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT06106308
<b>Title</b>	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-10-30
<b>Location</b>	Arizona, United States Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Bevacizumab, FOLFIRI, FOLFOX, Onvansertib
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03155061
<b>Title</b>	Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2017-05-16
<b>Location</b>	Japan
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	ONO-4538, ONO-4578, Opdivo
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05215574
<b>Title</b>	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
<b>Phase</b>	Phase 1

<b>Date Added</b>	2022-01-31
<b>Location</b>	Arizona, United States California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	NGM831, NGM831 plus pembrolizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03476681
<b>Title</b>	Study of NEO-201 in Solid Tumors Expansion Cohorts
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-03-26
<b>Location</b>	Maryland, United States Virginia, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	NEO-201 in combination with pembrolizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT06034860
<b>Title</b>	Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-09-13
<b>Location</b>	California, United States Indiana, United States Missouri, United States New York, United States Virginia, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	MT-8421, Nivolumab, Opdivo
<b>Tags</b>	MSI-H/ MMRd